JPH04224511A - Carrier for sustained release agent and its production - Google Patents
Carrier for sustained release agent and its productionInfo
- Publication number
- JPH04224511A JPH04224511A JP2406851A JP40685190A JPH04224511A JP H04224511 A JPH04224511 A JP H04224511A JP 2406851 A JP2406851 A JP 2406851A JP 40685190 A JP40685190 A JP 40685190A JP H04224511 A JPH04224511 A JP H04224511A
- Authority
- JP
- Japan
- Prior art keywords
- carrier
- drug
- raw material
- ceramic raw
- slurry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 32
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 claims abstract description 75
- 239000000919 ceramic Substances 0.000 claims abstract description 38
- 239000002994 raw material Substances 0.000 claims abstract description 28
- 239000002002 slurry Substances 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 229910010293 ceramic material Inorganic materials 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 72
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004068 calcium phosphate ceramic Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000004088 foaming agent Substances 0.000 claims description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000010304 firing Methods 0.000 claims description 2
- 238000005187 foaming Methods 0.000 claims description 2
- 239000012466 permeate Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 5
- 235000002906 tartaric acid Nutrition 0.000 abstract description 5
- 239000011975 tartaric acid Substances 0.000 abstract description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 3
- 239000003381 stabilizer Substances 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract description 2
- 239000001569 carbon dioxide Substances 0.000 abstract description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract description 2
- 239000006260 foam Substances 0.000 abstract description 2
- 229920002379 silicone rubber Polymers 0.000 abstract description 2
- 239000004945 silicone rubber Substances 0.000 abstract description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 description 10
- 239000011148 porous material Substances 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004604 Blowing Agent Substances 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
Landscapes
- Compositions Of Oxide Ceramics (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は、徐放剤用担体およびそ
の製造方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a carrier for sustained release drugs and a method for producing the same.
【０００２】0002
【従来の技術】癌、腫瘍、骨髄炎等の治療では、例えば
、抗癌剤や抗生物質が使用されている。しかし、これら
の薬剤には、重篤な副作用を有するものが多い。また、
これらの薬剤を全身投与しても、患部に作用する量は投
与量に対してわずかである。このため、薬剤を患部に選
択的にかつ適量を投与することができる薬剤投与方法が
検討されている。BACKGROUND OF THE INVENTION Anticancer agents and antibiotics, for example, are used in the treatment of cancer, tumors, osteomyelitis, and the like. However, many of these drugs have serious side effects. Also,
Even when these drugs are administered systemically, the amount that acts on the affected area is small compared to the dose administered. For this reason, drug administration methods that can selectively administer appropriate amounts of drugs to affected areas are being investigated.
【０００３】このような薬剤の投与方法として、生体内
患部に埋入して薬剤を徐々に放出させる徐放剤が提案さ
れている。例えば、特開昭５９−１０１１４５号公報に
は、多孔質セラミックス担体に薬剤を含浸させたものを
、患部に埋入して適量の薬剤を患部に供給することが開
示されている。また、特開昭６１−４７４０１号公報に
は、比表面積の大きいリン酸カルシウム系セラミックス
を基材として、このリン酸カルシウム系セラミック担体
に薬剤を吸着させた徐放剤が開示されている。[0003] As a method for administering such a drug, a sustained release drug has been proposed, which is implanted into an affected area in a living body and gradually releases the drug. For example, JP-A-59-101145 discloses that a porous ceramic carrier impregnated with a drug is implanted into the affected area to supply an appropriate amount of the drug to the affected area. Furthermore, Japanese Patent Application Laid-Open No. 61-47401 discloses a sustained release agent in which a calcium phosphate ceramic carrier having a large specific surface area is used as a base material, and a drug is adsorbed onto the calcium phosphate ceramic carrier.
【０００４】0004
【発明が解決しようとする課題】このような従来の徐放
剤では、薬剤を多孔質セラミックス担体に吸着させ、こ
れを患部に埋入した後に薬剤を脱離、放出させている。
しかしながら、多くの薬剤は多孔質セラミックス担体に
対して化学的に吸着されるのではなく、物理的に吸着さ
れる。このため、生体内に埋入すると短時間のうちに多
孔質セラミックス担体から薬剤が脱離、放出されてしま
う。この結果、薬剤を長期間、安定して患部に供給する
ことは困難であった。また、多孔質セラミックス担体の
気孔率や気孔径を変化させても、薬剤の放出量を制御す
ることが困難である等の問題があった。[Problems to be Solved by the Invention] In such conventional sustained release agents, the drug is adsorbed onto a porous ceramic carrier, and after this is implanted into the affected area, the drug is desorbed and released. However, many drugs are physically adsorbed onto porous ceramic carriers rather than chemically. Therefore, when implanted into a living body, the drug is desorbed and released from the porous ceramic carrier within a short period of time. As a result, it has been difficult to stably supply drugs to the affected area over a long period of time. Further, even if the porosity and pore diameter of the porous ceramic carrier were changed, there were other problems such as difficulty in controlling the amount of drug released.
【０００５】本発明は、かかる点に鑑みてなされたもの
であり、生体内に埋入して、薬剤を長期間にわたり選択
的かつ適量を患部に供給することができる徐放剤用担体
およびその製造方法を提供するものである。[0005] The present invention has been made in view of the above points, and provides a carrier for a sustained release drug that can be implanted in a living body to selectively and appropriately supply a drug to an affected area over a long period of time, and a carrier thereof. A manufacturing method is provided.
【０００６】[0006]
【課題を解決するための手段】本発明は、薬剤溶液を適
宜透過し得るセラミックス多孔体からなる担体本体と、
該担体本体の内部に化学的発泡により形成された、前記
薬剤溶液を保持し得る空間領域を有する薬剤保持孔とを
具備することを特徴とする徐放剤用担体である。ここで
、セラミックス多孔体としては、リン酸カルシウム系セ
ラミックス、アルミナ、ジルコニアまたはそれらの複合
材を使用することができる。[Means for Solving the Problems] The present invention provides a carrier body made of a porous ceramic material that can appropriately pass through a drug solution;
The present invention is a carrier for a sustained-release drug, characterized in that the carrier body is provided with a drug holding hole formed by chemical foaming inside the carrier body and having a space region capable of holding the drug solution. Here, as the ceramic porous body, calcium phosphate ceramics, alumina, zirconia, or a composite material thereof can be used.
【０００７】また、本発明は、所定形状の成形用型内に
セラミックス原料スラリーを充填する工程と、該セラミ
ックス原料スラリー内部に発泡剤を注入して気泡を発生
させる工程と、前記セラミックス原料スラリーを乾燥し
た後焼成して薬剤溶液を適宜透過し得るセラミックス多
孔体からなる担体本体を形成する工程とを具備すること
を特徴とする徐放剤用担体の製造方法である。The present invention also provides a step of filling a ceramic raw material slurry into a mold having a predetermined shape, a step of injecting a foaming agent into the ceramic raw material slurry to generate air bubbles, and a step of filling the ceramic raw material slurry with the ceramic raw material slurry. This is a method for producing a carrier for a sustained-release drug, which comprises a step of drying and then firing to form a carrier body made of a ceramic porous body that can appropriately permeate a drug solution.
【０００８】[0008]
【作用】本発明の徐放剤用担体によれば、薬剤溶液を適
宜透過し得るセラミックス多孔体からなる担体本体内部
に、化学反応によって形成された薬剤溶液を保持し得る
空間領域を有する薬剤保持孔が形成されている。これに
より、徐放剤用担体に薬剤溶液を含浸させると薬剤保持
孔に薬剤溶液が保持される。また、薬剤溶液を保持させ
た徐放剤用担体を生体内患部に埋入した際には、薬剤溶
液が担体本体の気孔を介して放出されるので、長期間に
わたり適量の薬剤が放出される。[Function] According to the carrier for a sustained release drug of the present invention, the drug holding body has a spatial region capable of holding a drug solution formed by a chemical reaction inside the carrier body made of a ceramic porous body that can appropriately pass the drug solution. A hole is formed. As a result, when the sustained-release drug carrier is impregnated with a drug solution, the drug solution is retained in the drug holding hole. In addition, when a carrier for a sustained-release drug holding a drug solution is implanted into an affected area in a living body, the drug solution is released through the pores of the carrier body, so an appropriate amount of drug is released over a long period of time. .
【０００９】また、本発明の徐放剤用担体の製造方法に
よれば、成形用型に充填したセラミックス原料スラリー
内部に発泡剤を注入する。これにより、発泡剤単独でま
たは他の物質との化学反応によってガスが発生し、セラ
ミックス原料スラリー内部に気泡が形成される。この後
、セラミックス原料スラリーを焼成すると、該気泡が薬
剤保持孔となる。According to the method for manufacturing a carrier for sustained release agents of the present invention, a foaming agent is injected into the ceramic raw material slurry filled in a mold. As a result, gas is generated by the blowing agent alone or by a chemical reaction with other substances, and bubbles are formed inside the ceramic raw material slurry. Thereafter, when the ceramic raw material slurry is fired, the bubbles become drug holding holes.
【００１０】0010
【実施例】以下、本発明の実施例について、図面を参照
して詳細に説明する。Embodiments Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings.
【００１１】図１は、セラミックス多孔体からなる球状
の担体本体１１の略中央に薬剤溶液を保持する複数の薬
剤保持孔１２を有する徐放剤用担体１０を示す断面図で
ある。ここで、担体本体１１を構成するセラミックス多
孔体としては、例えば、β−リン酸三カルシウム（β−
ＴＣＰ）や水酸化アパタイト等のリン酸カルシウム系セ
ラミックス、アルミナ、ジルコニア、またはそれらの複
合材を使用できる。特に、生体親和性が高いリン酸カル
シウム系セラミックスの多孔体が好ましい。FIG. 1 is a sectional view showing a sustained release drug carrier 10 having a plurality of drug holding holes 12 for holding a drug solution approximately in the center of a spherical carrier body 11 made of a porous ceramic material. Here, as the ceramic porous body constituting the carrier body 11, for example, β-tricalcium phosphate (β-
TCP), calcium phosphate ceramics such as hydroxyapatite, alumina, zirconia, or composites thereof can be used. In particular, porous bodies made of calcium phosphate ceramics, which have high biocompatibility, are preferred.
【００１２】担体本体１１の直径は、例えば、約８ｍｍ
であり、担体本体１１の気孔率は、薬剤保持孔１２に保
持された薬剤溶液が透過できる程度であり、約３０％の
気孔率が好ましい。また、薬剤保持孔１２の直径は、約
３００μｍ〜１ｍｍが好ましい。The diameter of the carrier body 11 is, for example, about 8 mm.
The porosity of the carrier body 11 is such that the drug solution held in the drug holding holes 12 can pass therethrough, and the porosity is preferably about 30%. Further, the diameter of the drug holding hole 12 is preferably approximately 300 μm to 1 mm.
【００１３】次に、かかる構成の徐放剤用担体１０は、
図２に示す如く、次のように製造する。まず、通常のメ
カノケミカル法によって合成したβ−ＴＣＰ粉末３０ｇ
に、気泡安定化剤６ｍｌ、水１２ｍｌ、炭酸水素ナトリ
ウム１．５ｇを加え、撹拌・混合してセラミックス原料
スラリーとする。次に、内径約８ｍｍのシリコンゴム製
の球体成形用割型２１に、セラミックス原料スラリー２
２を充填する。[0013] Next, the sustained release drug carrier 10 having such a structure is as follows:
As shown in FIG. 2, it is manufactured as follows. First, 30g of β-TCP powder synthesized by normal mechanochemical method.
6 ml of a bubble stabilizer, 12 ml of water, and 1.5 g of sodium hydrogen carbonate are added to the mixture and stirred and mixed to obtain a ceramic raw material slurry. Next, the ceramic raw material slurry 2 was placed in a split mold 21 made of silicone rubber with an inner diameter of about 8 mm for spherical molding.
Fill 2.
【００１４】次いで、セラミックス原料スラリー２２が
乾燥して固まる前に、球体成形用割型２１の開口部から
注射針２３をセラミックス原料スラリー２２の中心部ま
でさしこむ。次に、５重量％酒石酸水溶液を注入する。
すると、セラミックス原料スラリー２２中に含有された
炭酸水素ナトリウムと酒石酸が反応し、二酸化炭素が発
生する。この結果、セラミックス原料スラリー２２の中
心部に複数の気泡が形成される。気泡の数および体積は
、注入する酒石酸水溶液の量を調節することによって設
定できる。Next, before the ceramic raw material slurry 22 dries and hardens, the injection needle 23 is inserted into the center of the ceramic raw material slurry 22 through the opening of the sphere molding split mold 21. Next, a 5% by weight aqueous tartaric acid solution is injected. Then, the sodium bicarbonate contained in the ceramic raw material slurry 22 reacts with tartaric acid, and carbon dioxide is generated. As a result, a plurality of bubbles are formed in the center of the ceramic raw material slurry 22. The number and volume of bubbles can be set by adjusting the amount of aqueous tartaric acid solution injected.
【００１５】気泡形成のその他の例として、発泡剤に過
酸化水素水を使用して次のように行うことができる。ま
ず、β−ＴＣＰ粉末に、気泡安定化剤６ｍｌ、水１２ｍ
ｌだけを加えて撹拌・混合したセラミックス原料スラリ
ーを、上述と同様に、成形用割型に充填する。この後、
過酸化水素水を注射針でセラミックス原料スラリーの中
心部に注入する。すると、過酸化水素から酸素が発生し
、セラミックス原料スラリーの中心部に気泡が形成され
る。このように気泡を形成した後、セラミックス原料ス
ラリー２２を乾燥し、成形用割型２１から取り出し、１
０５０℃で１時間焼成して徐放剤用担体１０を得た。As another example of foam formation, hydrogen peroxide solution can be used as a foaming agent in the following manner. First, add β-TCP powder, 6 ml of bubble stabilizer, and 12 ml of water.
The ceramic raw material slurry, which is stirred and mixed by adding only 1, is filled into a split mold for molding in the same manner as described above. After this,
Inject hydrogen peroxide into the center of the ceramic raw material slurry using a syringe needle. Then, oxygen is generated from hydrogen peroxide, and bubbles are formed in the center of the ceramic raw material slurry. After forming the bubbles in this way, the ceramic raw material slurry 22 is dried, taken out from the molding mold 21, and
A sustained release agent carrier 10 was obtained by baking at 050° C. for 1 hour.
【００１６】得られた徐放剤用担体１０を、抗生物質や
抗癌剤の薬剤溶液に浸漬して、これを減圧雰囲気下に供
することにより、担体本体１１の気孔を介して、薬剤保
持孔１２に薬剤溶液を保持させることができる。The obtained sustained-release drug carrier 10 is immersed in a drug solution of an antibiotic or an anticancer drug, and is subjected to a reduced pressure atmosphere, so that the drug is absorbed into the drug holding hole 12 through the pores of the carrier body 11. A drug solution can be retained.
【００１７】薬剤溶液を保持させた徐放剤用担体１０を
、生理食塩水中に浸漬し、放出される薬剤濃度を経時的
に測定した結果、従来の気孔率４０％のβ−ＴＣＰ多孔
体に本実施例と同様の薬剤溶液を含浸させたものと比較
しても、長期間にわたって薬剤を放出できることが確認
された。The sustained release drug carrier 10 holding the drug solution was immersed in physiological saline and the released drug concentration was measured over time. It was confirmed that the drug could be released over a long period of time even when compared with a product impregnated with the same drug solution as in this example.
【００１８】上記説明したように、徐放剤用担体１０に
よれば、生体内の患部近傍に徐放剤用担体１０を埋入し
た場合、薬剤保持孔１２に保持された薬剤溶液は、担体
本体１１の気孔を介して外部に放出される。このため、
適量の薬剤溶液を長期間にわたって放出させることがで
きる。この結果、薬剤を患部に選択的にかつ長期間にわ
たって供給できるため、少量の薬剤投与でも十分な治療
効果を上げることができると共に、重篤な副作用を軽減
できる。また、担体本体１１の気孔率、気孔径、または
厚さを変化させることによって、薬剤溶液の透過性を変
更し、薬剤の放出量を容易に制御することができる。As explained above, according to the sustained-release drug carrier 10, when the sustained-release drug carrier 10 is implanted near the affected area in a living body, the drug solution held in the drug holding hole 12 is transferred to the carrier. It is released to the outside through the pores of the main body 11. For this reason,
Appropriate amounts of drug solution can be released over an extended period of time. As a result, the drug can be selectively supplied to the affected area over a long period of time, so that sufficient therapeutic effects can be achieved even with a small amount of drug administration, and serious side effects can be reduced. Furthermore, by changing the porosity, pore diameter, or thickness of the carrier body 11, the permeability of the drug solution can be changed and the amount of drug released can be easily controlled.
【００１９】また、担体本体１１が生体親和性が高くか
つ吸収性の優れたβ−ＴＣＰで構成されている。このた
め、徐放剤用担体１０を生体内に埋入した場合に、治療
終了後に取り出す必要がない。徐放剤用担体１０を骨組
織中に埋入する場合には、担体本体１１をβ−ＴＣＰで
構成すると経時的に自家骨化するので特に好ましい。Further, the carrier body 11 is made of β-TCP which has high biocompatibility and excellent absorbability. Therefore, when the sustained-release drug carrier 10 is implanted in a living body, there is no need to take it out after the completion of treatment. When the sustained-release agent carrier 10 is to be implanted in bone tissue, it is particularly preferable that the carrier body 11 be made of β-TCP because it will become autogenously ossified over time.
【００２０】[0020]
【発明の効果】以上説明した如くに、本発明の徐放剤用
担体によれば、セラミックス多孔体からなる担体本体内
部に、薬剤保持孔が形成されている。これによって、徐
放剤用担体を薬剤溶液に浸漬させて、薬剤保持孔に薬剤
溶液を保持させることができる。さらに、薬剤溶液を保
持させた徐放剤用担体を生体内に埋入した際には、薬剤
保持孔から薬剤溶液が担体本体の気孔を介して放出され
るため、適量の薬剤を患部に長期間にわたって選択的に
供給できる。この結果、少量の薬剤投与でも十分な治療
効果を上げることができると共に、重篤な副作用を軽減
できるものである。As explained above, according to the carrier for a sustained release drug of the present invention, drug holding holes are formed inside the carrier body made of a porous ceramic material. Thereby, the sustained release drug carrier can be immersed in the drug solution, and the drug solution can be held in the drug holding holes. Furthermore, when a sustained-release drug carrier holding a drug solution is implanted into a living body, the drug solution is released from the drug-retaining pores through the pores of the carrier body, allowing an appropriate amount of drug to be delivered to the affected area over a long period of time. Can be selectively supplied over a period of time. As a result, sufficient therapeutic effects can be achieved even with a small amount of drug administration, and serious side effects can be reduced.
【００２１】また、本発明の徐放剤用担体の製造方法に
よれば、セラミックス原料スラリー内部に発泡剤を注入
し、化学反応によりガスを発生させる。これにより、セ
ラミックス原料スラリー内部に気泡を形成した後、セラ
ミックス原料スラリーを乾燥・焼成することによって、
担体本体内部に薬剤保持孔を容易に形成することができ
る。Further, according to the method for manufacturing a carrier for a sustained release agent of the present invention, a foaming agent is injected into the ceramic raw material slurry and gas is generated by a chemical reaction. By this, after forming air bubbles inside the ceramic raw material slurry, the ceramic raw material slurry is dried and fired.
Drug holding holes can be easily formed inside the carrier body.
【図１】本発明の徐放剤用担体の一実施例を示す断面図
。FIG. 1 is a cross-sectional view showing one embodiment of the carrier for sustained-release drugs of the present invention.
【図２】本発明の徐放剤用担体の製造方法の一工程を示
す説明図。FIG. 2 is an explanatory diagram showing one step of the method for producing a carrier for a sustained-release drug of the present invention.
１０…徐放剤用担体、１１…担体本体、１２…薬剤保持
孔、２１…成形用割型、２２…セラミックス原料スラリ
ー、２３…注射針。DESCRIPTION OF SYMBOLS 10... Carrier for sustained release agent, 11... Carrier main body, 12... Drug holding hole, 21... Split mold for molding, 22... Ceramic raw material slurry, 23... Injection needle.
Claims (3)
ス多孔体からなる担体本体と、該担体本体の内部に化学
的発泡により形成された、前記薬剤溶液を保持し得る空
間領域を有する薬剤保持孔とを具備することを特徴とす
る徐放剤用担体。1. A carrier body made of a porous ceramic material that can appropriately permeate a drug solution, and a drug holding hole formed inside the carrier body by chemical foaming and having a spatial region capable of holding the drug solution. A carrier for a sustained release agent, comprising:
ウム系セラミックス、アルミナ、ジルコニアまたはそれ
らの複合材からなる第１項記載の徐放剤用担体。2. The sustained-release carrier according to claim 1, wherein the porous ceramic body is composed of calcium phosphate ceramics, alumina, zirconia, or a composite thereof.
原料スラリーを充填する工程と、該セラミックス原料ス
ラリー内部に発泡剤を注入して気泡を発生させる工程と
、前記セラミックス原料スラリーを乾燥した後焼成して
薬剤溶液を適宜透過し得るセラミックス多孔体からなる
担体本体を形成する工程とを具備することを特徴とする
徐放剤用担体の製造方法。3. A step of filling a ceramic raw material slurry into a mold having a predetermined shape, a step of injecting a foaming agent into the ceramic raw material slurry to generate air bubbles, and a step of firing the ceramic raw material slurry after drying it. 1. A method for producing a carrier for a sustained-release drug, the method comprising the step of: forming a carrier body made of a porous ceramic material that can appropriately transmit a drug solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2406851A JPH04224511A (en) | 1990-12-26 | 1990-12-26 | Carrier for sustained release agent and its production |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2406851A JPH04224511A (en) | 1990-12-26 | 1990-12-26 | Carrier for sustained release agent and its production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04224511A true JPH04224511A (en) | 1992-08-13 |
Family
ID=18516470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2406851A Withdrawn JPH04224511A (en) | 1990-12-26 | 1990-12-26 | Carrier for sustained release agent and its production |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04224511A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018038031A1 (en) * | 2016-08-24 | 2018-03-01 | 旭硝子株式会社 | Method for molding ceramic material, method for producing ceramic article, and ceramic article |
| WO2020146901A1 (en) * | 2019-01-12 | 2020-07-16 | The Research Foundation For The State University Of New York | Ceramic foams, methods of making same, and uses thereof |
| WO2020153376A1 (en) * | 2019-01-21 | 2020-07-30 | 日東電工株式会社 | Film |
| JP2020138888A (en) * | 2019-02-28 | 2020-09-03 | 日鉄日新製鋼株式会社 | Ceramics production method and ceramics |
-
1990
- 1990-12-26 JP JP2406851A patent/JPH04224511A/en not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018038031A1 (en) * | 2016-08-24 | 2018-03-01 | 旭硝子株式会社 | Method for molding ceramic material, method for producing ceramic article, and ceramic article |
| JPWO2018038031A1 (en) * | 2016-08-24 | 2019-06-20 | Ａｇｃ株式会社 | Method of forming ceramic material, method of manufacturing ceramic article, and ceramic article |
| US11572316B2 (en) | 2016-08-24 | 2023-02-07 | AGC Inc. | Method for molding ceramic material, method for producing ceramic article, and ceramic article |
| WO2020146901A1 (en) * | 2019-01-12 | 2020-07-16 | The Research Foundation For The State University Of New York | Ceramic foams, methods of making same, and uses thereof |
| CN113795472A (en) * | 2019-01-12 | 2021-12-14 | 纽约州立大学研究基金会 | Ceramic foam, method for the production thereof and use thereof |
| CN113795472B (en) * | 2019-01-12 | 2023-08-04 | 纽约州立大学研究基金会 | Ceramic foam, method for producing same and use thereof |
| WO2020153376A1 (en) * | 2019-01-21 | 2020-07-30 | 日東電工株式会社 | Film |
| CN113329869A (en) * | 2019-01-21 | 2021-08-31 | 日东电工株式会社 | Film |
| JP2020138888A (en) * | 2019-02-28 | 2020-09-03 | 日鉄日新製鋼株式会社 | Ceramics production method and ceramics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2702953B2 (en) | Chemical impregnated ceramics | |
| JP3720386B2 (en) | Drug release controlled formulation | |
| KR100584632B1 (en) | Controlled release preparations having multi-layer structure | |
| KR950003920B1 (en) | Dispenser which delivers a drug in a carrier that diffuses therefrom by self-power | |
| EP0862416B1 (en) | Non-polymeric sustained release delivery system | |
| US6719989B1 (en) | Sustained release drug carrier, and method of manufacturing sustained release drug carrier | |
| JP2006519252A5 (en) | ||
| ES2909417T3 (en) | Bioactive Porous Bone Graft Implants | |
| JPS63239212A (en) | Pulsing sustained release drug | |
| CN103040727A (en) | Preparation method of drug and protein sustained-release alginate hybrid gel | |
| JPH06509809A (en) | Dosage forms that release the drug in a short period of time | |
| CA2833997A1 (en) | Method and apparatus for nitric oxide generation | |
| EA200101206A1 (en) | APPLICATION OF BIORABLABLE MICROSPHERES, RELAXING ANTI-SCIENT AGENT, FOR TREATMENT OF GLYOBLASTOMA | |
| CN112999364B (en) | Preparation method of hollow mesoporous silica dual-drug sustained-release microspheres for treating osteoporosis | |
| CN101461943A (en) | Micropore ceramics and method for sustained-release of medicament or biological preparation and use thereof | |
| CN107438432B (en) | Soluble microneedles for protein or peptide delivery | |
| US20050158395A1 (en) | Device and method for producing a cross-linked substance, especially in the form of a microcapsule or layer | |
| JP2005046530A (en) | Porous calcium phosphate hardened body, method of manufacturing the same, and artificial bone and medicine controlled release body using the same | |
| TW201343204A (en) | A drug delivery system | |
| JPH04224511A (en) | Carrier for sustained release agent and its production | |
| JP3635316B2 (en) | Method for producing spherical ceramic porous body | |
| CN101269049B (en) | Phosphoric acid ligustrazine micropore permeation pump control-release tablet and preparation method thereof | |
| JPH04327525A (en) | Sustained release medicine-containing ceramic porous substance | |
| JP3152665B2 (en) | Carrier for sustained release agent and method for producing the same | |
| JP3122669B2 (en) | Sustained release agent and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 19980312 |